Menopause Clinical Trials: How to Find the Right Study for You

What Menopause Actually Is (and What It Is Not)

Menopause is a single day, technically. It is the 12-month anniversary of your final menstrual period, confirmed only in retrospect. The Menopause Society defines it as the permanent cessation of menstruation resulting from loss of ovarian follicular activity. The average age at natural menopause in the United States is 51.4 years.

Everything before that 12-month mark is perimenopause.

Perimenopause: The Stage Most Women Are Actually In

Perimenopause can last four to eight years and is defined by irregular cycles, fluctuating estrogen and FSH levels, and the onset of symptoms. This is when vasomotor symptoms (VMS), sleep disruption, mood changes, and irregular bleeding most commonly begin. FSH alone is not a reliable diagnostic marker in this stage because levels fluctuate day to day.

If you are still having periods, even irregular ones, you are in perimenopause, not menopause. This distinction matters enormously for clinical trial eligibility, since many studies enroll based on FSH thresholds, cycle history, or confirmed postmenopausal status.

Surgical and Premature Menopause

Surgical menopause, caused by bilateral oophorectomy, is abrupt. Estrogen levels drop within hours rather than years. Women who experience surgical menopause before age 45 face a higher risk of cardiovascular disease, cognitive decline, and osteoporosis compared with those who reach natural menopause at the average age, according to a 2021 ACOG Practice Bulletin. Premature ovarian insufficiency (POI), defined as menopause before age 40, affects approximately 1% of women and carries its own distinct trial field.

The Core Symptoms: What Trials Are Targeting

Vasomotor Symptoms

Hot flashes and night sweats, collectively called VMS, affect up to 80% of women during the menopausal transition. The SWAN (Study of Women's Health Across the Nation) cohort found that VMS persist for a median of 7.4 years from first onset, and longer in women who begin symptoms before their final menstrual period. Black women in SWAN experienced the longest duration of VMS, a finding that shapes which populations many new trials are trying to recruit.

Most menopause clinical trials currently recruiting fall into one of three VMS categories:

• Hormone therapy formulations (new delivery routes, bioidentical vs. Synthetic comparisons)
• Neurokinin B pathway antagonists (fezolinetant is now FDA-approved; trials test next-generation agents)
• Non-hormonal options including SSRIs, SNRIs, gabapentin, and oxybutynin

Genitourinary Syndrome of Menopause

GSM covers vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs caused by hypoestrogenism of the vulvovaginal tissues. It affects approximately 50% of postmenopausal women but is under-reported and under-treated. Unlike VMS, GSM does not improve spontaneously over time. Trials in this space test local vaginal estrogen, dehydroepiandrosterone (prasterone/Intrarosa), ospemifene, and novel laser-based therapies.

Bone Density and Fracture Risk

Women lose an estimated 20% of bone density in the five to seven years immediately following menopause due to estrogen withdrawal. The FRAX tool uses femoral neck BMD alongside clinical risk factors to calculate 10-year fracture probability. Trials in this area test bisphosphonates, denosumab, romosozumab, and the role of hormone therapy on bone mineral density outcomes in the early postmenopausal window.

Cardiovascular and Metabolic Risk

Estrogen loss accelerates atherogenic lipid changes, including rising LDL and declining HDL. The Women's Health Initiative (WHI), which enrolled 161,808 postmenopausal women, remains the largest randomized trial of menopausal hormone therapy and cardiovascular outcomes. More recent reanalysis of WHI data by age and time since menopause supports the "timing hypothesis": hormone therapy started within 10 years of menopause or before age 60 does not increase, and may reduce, coronary heart disease risk in otherwise healthy women, a position endorsed by The Menopause Society 2022 Position Statement.

How to Find a Menopause Clinical Trial

The trial-finding process is practical and specific. Here is a step-by-step approach built for women, not researchers.

Step 1: Identify Your Primary Symptom Burden

Trials recruit around specific endpoints. Before you search, write down:

1. Your most disabling symptom (VMS, GSM, mood, sleep, sexual dysfunction, bone loss)
2. Your menopause status (perimenopausal, recently postmenopausal, or more than 5 years post-FMP)
3. Your hormone therapy history (naive, current user, past user, more than 5 years off)
4. Relevant comorbidities (breast cancer history, cardiovascular disease, diabetes, autoimmune conditions)

These four data points will determine your eligibility for roughly 80% of trials before you read a single inclusion criterion.

Step 2: Use ClinicalTrials.gov Correctly

Go to ClinicalTrials.gov and search "menopause" with the condition filter set to your primary symptom. Filter by:

• Status: Recruiting
• Study type: Interventional (for treatment trials) or Observational (for natural-history or biomarker studies)
• Age: Enter your current age
• Sex: Female (this filters out mixed-sex studies where women are enrolled as a secondary population)

The site lists over 1,000 menopause-related studies. Narrowing by your symptom and status typically brings this to 30 to 80 actionable options.

Step 3: Check Eligibility Criteria Line by Line

Every trial has inclusion and exclusion criteria. Pay close attention to:

• FSH threshold: Many trials require FSH >40 mIU/mL to confirm postmenopausal status
• Amenorrhea duration: Some trials require at least 12 months; others accept 6 months with confirmed FSH
• BMI limits: Trials sometimes exclude BMI >35 or <18, which disproportionately affects women of color and women with metabolic conditions
• Washout periods: If you use hormone therapy, estrogen, or antidepressants, you may need a 4-to-12-week washout before enrollment
• Contraception requirements: If you are perimenopausal and premenopausal (still at risk of pregnancy), most drug trials require documented reliable contraception

Step 4: Contact the Trial Coordinator Directly

The listed principal investigator contact is usually a study coordinator, not the physician. Email or call with a brief summary: your age, menopause status, primary symptom, and current medications. Most coordinators will pre-screen you in 10 minutes over the phone and tell you whether a full screening visit is worth your time.

Step 5: Evaluate the Consent Form Before You Visit

Request the informed consent form before your screening appointment. Review the visit schedule, time commitment, travel requirements, and compensation. A 12-week VMS drug trial may require eight in-person visits; a digital observational study may require only an app and quarterly questionnaires. Know what you are signing up for before you clear your schedule.

Major Active Trial Areas in 2025

Neurokinin B Antagonists Beyond Fezolinetant

Fezolinetant (Veozah) was FDA-approved in May 2023 for moderate-to-severe VMS due to menopause, at 45 mg orally once daily. It is the first non-hormonal NK3 receptor antagonist approved for this indication. Phase 3 trials of next-generation NK3B antagonists are actively recruiting, some targeting women who failed or did not tolerate fezolinetant. These trials are non-hormonal and appropriate for women with hormone-sensitive breast cancer history or personal preference against hormone therapy.

Hormone Therapy: New Routes and Timing Studies

Despite the WHI's landmark data, questions remain about optimal delivery route, dose, and duration. Current trials are examining:

• Transdermal estradiol versus oral estradiol and VTE risk (oral estrogen carries a higher clot risk than transdermal in observational data)
• Low-dose vaginal estrogen in women with breast cancer receiving aromatase inhibitors
• Testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women (testosterone is not FDA-approved for this indication in women; trials are ongoing)

The WISDOM Trial and Personalized HRT

The WISDOM trial (Women's International Study of Long Duration Oestrogen after Menopause) is a pragmatic UK-based randomized controlled trial comparing long-term versus short-term hormone therapy outcomes, including quality of life, cardiovascular, and breast cancer endpoints. Enrollment data have informed the discussion around individualized rather than blanket time-limited prescribing.

Ospemifene and GSM in Breast Cancer Survivors

Ospemifene, an oral selective estrogen receptor modulator (SERM), is FDA-approved for moderate-to-severe dyspareunia due to GSM at 60 mg daily. Trials are actively studying its safety profile in breast cancer survivors who cannot use local estrogen, a population with high unmet need and almost no evidence base from large randomized trials.

Women at the Margins: Who Is Left Out of Menopause Research

Most menopause trials to date have enrolled predominantly white, college-educated, and healthy women. This is not a minor caveat. The SWAN cohort data showed that Black women report more severe and longer-duration VMS than white women, yet they remain under-enrolled in treatment trials. Hispanic and Asian women have distinct hormonal trajectories through the menopausal transition that are not well-represented in trial populations.

A practical framework for evaluating whether a trial will produce data relevant to you:

| Factor | What to ask the coordinator | |---|---| | Race/ethnicity enrollment targets | Does the study have an equity recruitment goal? | | BMI range | Is the upper BMI limit above 35? | | Comorbidity profile | Are women with hypertension, diabetes, or depression eligible? | | Geographic access | Are remote visits or telehealth screening available? | | Language | Is the consent form available in your primary language? |

If a trial cannot answer these questions clearly, that is itself meaningful information about how it will generalize to your health situation.

Perimenopause Specifically: Your Trial Options Are Different

If you are in perimenopause, still cycling, or within the first 12 months of amenorrhea, your trial eligibility profile differs significantly from a woman who has been postmenopausal for five years. Most bone density and cardiovascular outcome trials require confirmed postmenopausal status. VMS trials often accept perimenopausal women if they meet FSH criteria and have documented irregular cycles.

Perimenopause is also when fertility-contraception overlap becomes clinically relevant, and this shapes which drug trials you can enter.

Pregnancy, Contraception, and Perimenopause: What You Must Know

Perimenopause does not equal infertility. Spontaneous ovulation continues, often unpredictably, until the final menstrual period. Women in perimenopause can and do conceive, and unintended pregnancy carries higher obstetric risk after age 40, including increased rates of chromosomal aneuploidy, gestational diabetes, and hypertensive disorders.

ACOG Practice Bulletin No. 141 recommends contraception until 12 months after the final menstrual period for women going through natural menopause. This is not an optional consideration in clinical trials. Drug trials in perimenopausal women universally require documented use of at least one highly effective contraceptive method during the trial and typically for 30 days to 90 days after the final dose, depending on the investigational agent.

If a trial tests a potentially teratogenic compound (some SERM-class agents, investigational neurokinin antagonists, and certain metabolic drugs), a negative pregnancy test at screening and at each study visit may be required. Non-hormonal contraceptive options such as the copper IUD are often preferred in hormone-sensitive study populations to avoid confounding the treatment signal.

Hormone therapy itself, when studied in clinical trials, is not considered a contraceptive. Low-dose oral contraceptives, which both manage perimenopausal symptoms and provide contraception, are a separate treatment category. Several trials are now evaluating low-dose combined oral contraceptives as perimenopausal symptom management, making OCP use a study intervention rather than a contraindication.

Postmenopausal women, confirmed by 12 months of amenorrhea, do not require contraception and face no pregnancy-related trial restrictions.

Who Should Consider a Clinical Trial (and Who Should Not)

Good Candidates for Menopause Trials

• Women with moderate-to-severe VMS who have not found adequate relief with available treatments
• Women who prefer non-hormonal options and want access to investigational NK3B antagonists
• Women with a personal or family history of breast cancer who need GSM treatment but cannot use estrogen
• Postmenopausal women with osteopenia who want to evaluate newer bone-protective agents
• Women motivated by contributing to a dataset that will improve care for future patients, particularly women of color

Women Who Should Approach Trials With Caution

• Women with active breast cancer receiving systemic therapy (some trials are specifically designed for this group, but many are not)
• Women with recent cardiovascular events (within 12 months of a stroke or MI), who face exclusion from most hormone therapy trials
• Women who require medications incompatible with common trial washout requirements
• Women whose work, caregiving, or transportation constraints make frequent in-person visits unrealistic

None of these situations is an absolute barrier across all trials. An observational study or a digital-only trial may suit you even when an interventional pharmacology study does not.

Evaluating Trial Quality: What to Look For

Not all clinical trials carry the same evidence weight. Here is how to read a trial's design quickly.

Phase and Purpose

• Phase 1: Safety and dose-finding in small groups. Early-stage; not appropriate if you want treatment access.
• Phase 2: Efficacy signal testing. Small sample sizes; preliminary results.
• Phase 3: Confirmatory trials in hundreds to thousands of women. These generate the data that lead to FDA approval.
• Phase 4 / Post-marketing: Studies of approved drugs in real-world populations, often with broader eligibility.

Most women seeking treatment access will benefit most from Phase 2b or Phase 3 trials.

Endpoints That Matter to Women

Ask whether the trial's primary endpoint is one you actually care about. A bone mineral density trial measuring lumbar spine DXA scores at 12 months tells you less about your fracture risk than a trial measuring vertebral fracture incidence over 3 years. A VMS trial measuring frequency and severity of hot flashes using a validated diary is more meaningful than one using only a global impression score.

The Menopause Society recommends that VMS trials use both frequency and severity as co-primary endpoints, and any trial that measures only frequency may undercount the burden on quality of life.

Placebo Arms and What They Mean

Many women are reluctant to join a placebo-controlled trial. In menopause VMS trials, placebo response rates are high, sometimes 30-50% reduction in hot flash frequency, which reflects real neurobiological mechanisms, not just expectation. This means even the placebo arm provides structured monitoring, regular clinical contact, and a validated diary system, which many women find clinically useful in itself.

Practical Questions to Ask Any Trial Team

Before signing the consent form, ask these directly:

1. What are you testing and what is the comparator?
2. What is my probability of receiving placebo versus active treatment?
3. What happens to my current medications during the trial?
4. Are there trial-related costs I will bear (travel, childcare, time off work)?
5. Will I receive my lab results and bone scans?
6. What happens if I have an adverse reaction?
7. Will I be notified of the trial results when they publish?
8. Is my data de-identified and how is it protected?

A trial team that cannot answer questions 1 through 6 clearly before you sign is a team that will not communicate well during the study either.

After the Trial: What Happens to Your Care

Participation does not guarantee continued access to the investigational drug after the trial ends. Ask explicitly about:

• Open-label extension: Some trials offer continued treatment access after the blinded phase ends.
• Compassionate use / expanded access: For promising drugs not yet approved, this pathway may exist through the FDA.
• Care coordination: Confirm that your primary clinician or menopause specialist will receive a summary of your participation, including any labs or imaging done during the trial.

ACOG advises that menopause management should be individualized and re-evaluated at least annually, which means trial participation fits best when it is part of an ongoing clinical relationship, not a substitute for one.